Huons Lab Registers Patent for ADC SC Formulation Incorporating HyDIFFUZE Platform

"Improved Stability and Drug Diffusion of ADC SC Formulation"

Huons Lab announced on July 27, 2026, that it has recently completed the registration of a patent for its subcutaneous (SC) antibody-drug conjugate (ADC) formulation incorporating the human-derived hyaluronidase-based platform technology, 'HyDIFFUZE(TM)'.

This patent covers the SC formulation technology of ADCs that utilize HyDIFFUZE, including formulation technologies designed for developing ADC subcutaneous injections. Based on research findings, the company expects that ADC SC formulations developed with HyDIFFUZE will improve initial absorption and enhance in vivo drug exposure.

The research results were presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) in March 2026. Through this patent registration, Huons Lab has also secured intellectual property rights to the core technology of ADC SC formulations.

Huons Lab is also pursuing approval from the Ministry of Food and Drug Safety for its standalone recombinant hyaluronidase product, 'HyDEZyme Injection,' with the goal of obtaining product approval within this year.

A company representative stated, "We will continue to advance the HyDIFFUZE platform technology, expand its application to various next-generation biopharmaceuticals, and further strengthen the platform's competitiveness through global business development."

This content was produced with the assistance of AI translation services.